Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Passage Bio, Inc. (NASDAQ: PASG) announced that CEO Bruce Goldsmith will participate in a virtual panel at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference, scheduled for August 10-12, 2021. Goldsmith's participation is set for August 11 at 8:35 a.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 30 days post-event. Passage Bio is dedicated to developing gene therapies for rare central nervous system disorders and has a collaboration with the University of Pennsylvania’s Gene Therapy Program.

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio, will participate in a virtual panel presentation at the upcoming 12^th Annual Wedbush PacGrow Healthcare Virtual Conference, taking place on August 10-12, 2021.

Format: Panel
Date: Wednesday, August 11, 2021
Time: 8:35 a.m. ET

A live webcast of the events will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the presentations will be available for 30 days following the events.

About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com

 

FAQ

When will Bruce Goldsmith speak at the Wedbush PacGrow Healthcare Virtual Conference for PASG?

Bruce Goldsmith will speak on August 11, 2021, at 8:35 a.m. ET.

How can I watch the Passage Bio presentation at the conference?

The presentation will be available via live webcast on the Investors & News section of Passage Bio's website.

What is the focus of Passage Bio's therapies?

Passage Bio focuses on developing gene therapies for rare, monogenic central nervous system disorders.

What is the date range for the Wedbush PacGrow Healthcare Virtual Conference?

The conference takes place from August 10 to August 12, 2021.

Where is Passage Bio located?

Passage Bio is based in Philadelphia, PA.